Global Ganja Report

Israel's internal market for medical cannabis products is limited by the country's relatively small population, but with exports now approved by the cabinet, a multi-billion-dollar industry is foreseen. Since the announcement, share prices of cannabis companies on the Tel Aviv Stock Exchange have soared.

California's ArcView Market Research and its affiliated BDS Analytics have released a "2019 Update" to the 6th edition of their report on The State of Legal Marijuana Markets, which was published back in June. The Update takes stock of events in the second half of the year, and anticipates that worldwide spending on legal cannabis will grow 39.1% to $17 billion in 2019.

A contraband cannabis economy booms in the Balkan Peninsula, where the wars of the 1990s spurred an underground dope-for-guns network that still thrives today. But amid EU pressure to crack down, a legal industry is now starting to emerge.

Two bills to legalize "recreational" cannabis have been introduced in Portugal—a country that already has a thriving medical marijuana industry, and a "depenalization" policy for personal possession that has been hailed as a success by reform advocates across the world.

A Chinese delegation to Israel to explore cooperation in the cannabis sector points to the East Asian giant's growing footprint in the global industry. But in a continued contradiction, the People's Republic has possibly the harshest drug laws on Earth—and, where unsanctioned use by the commoners is concerned, cannabis is no exception.

In a strange irony, Vancouver is shutting down its long-tolerated but unlicensed cannabis dispensaries, pursuant to a British Columbia high court decision upholding its right to do so—even as the province struggles to meet demand amid a dearth of licensed retail outlets.

In Episode 24 of the CounterVortex podcast, Bill Weinberg notes the historic strides toward liberation of the cannabis plant in 2018, from the fabled four corners of the Earth. Yet under capitalism, every advance also opens new contradictions.

With passage of the Farm Bill and removal of hemp-derived CBD from controlled substance status, big market growth is expected for the very chic and purportedly salubrious non-psychoactive cannabinoid. The law is a win for a nascent CBD industry that has been struggling to shake off the lingering stigma surrounding (psychoactive) cannabis. The effort to segment cannabidiol from "marijuana" is exemplified in the several states that now have "CBD-only" laws.